Literature DB >> 25213764

Genetic polymorphisms of inflammatory response gene TNF-α and its influence on sporadic pancreatic neuroendocrine tumors predisposition risk.

Dimitrios Karakaxas1, Maria Gazouli, Ahmet Coker, Christos Agalianos, Ioannis S Papanikolaou, Pavlos Patapis, Theodoros Liakakos, Christos Dervenis.   

Abstract

The diagnosed incidence of pancreatic neuroendocrine tumors (pNETs) is increasing; however, their etiology remains poorly understood. PNETs are a rare, heterogeneous group of tumors arising from the endocrine cells of the pancreas, and genetic risk factors for sporadic pNETs are inadequately understood. It is known that pNETs secrete biogenic amines, hormones and growth factors, tumor necrosis factor-a (TNF-α) being one of them. Furthermore, cytokines and other proinflammatory mediators have been implicated in inflammatory pancreatic diseases including pancreatitis and cancer. The aim of our study was to analyze TNF-α promoter gene polymorphisms as risk factors for pNETs using germline DNA collected in a population-based case-control study of pancreatic cancer [42 pNET cases, 78 pancreatic ductal adenocarcinoma (PDAC) cases, 17 intraductal papillary mucinous neoplasm (IPMN) and 98 healthy controls] conducted in the Athens, Greece and Izmir, Turkey areas. For subsequent analysis, we excluded cases and controls with known genetic syndromes. The CC genotype at the -1031 position was more frequent in pNET and IPMN patients (p=0.0002 and p=0.009, respectively), suggesting its possible role in pNET development. Furthermore, the AA genotype at the -308 position was overrepresented in IPMN cases (p=0.03), and AA genotype at the -238 position was more frequent in PDAC cases (p=0.03) compared to healthy individuals. With regard to tumor characteristics, no statistically significant association was detected. Our findings suggest the putative role of TNF-α -1031 polymorphism in the development of pNET and IPMN, whereas the -308 polymorphism seems to be overrepresented among IPMN cases and -238 polymorphism among PDAC cases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25213764     DOI: 10.1007/s12032-014-0241-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  20 in total

Review 1.  Cytokine gene polymorphism in human disease: on-line databases.

Authors:  J Bidwell; L Keen; G Gallagher; R Kimberly; T Huizinga; M F McDermott; J Oksenberg; J McNicholl; F Pociot; C Hardt; S D'Alfonso
Journal:  Genes Immun       Date:  1999-09       Impact factor: 2.676

2.  Association between EGF, TGF-{beta}1, TNF-{alpha} gene polymorphisms and cancer of the pancreatic head.

Authors:  Guo-Yang Wu; Qingjun Lu; Till Hasenberg; Marco Niedergethmann; Stefan Post; Jörg W Sturm; Michael Keese
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

Review 3.  Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment.

Authors:  Kjell Oberg
Journal:  Curr Opin Oncol       Date:  2002-01       Impact factor: 3.645

Review 4.  Neuroendocrine neoplasms of the gut and pancreas: new insights.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2011-08-02       Impact factor: 43.330

5.  Two polymorphisms of the tumour necrosis factor gene do not influence survival in pancreatic cancer.

Authors:  M D Barber; J J Powell; S F Lynch; N J Gough; K C Fearon; J A Ross
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

6.  Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma.

Authors:  Eric J Duell; Daniel P Casella; Robert D Burk; Karl T Kelsey; Elizabeth A Holly
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-04       Impact factor: 4.254

Review 7.  Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer.

Authors:  G Mark Anderson; Marian T Nakada; Mark DeWitte
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

Review 8.  Tumour biology of gastroenteropancreatic neuroendocrine tumours.

Authors:  Carsten Grötzinger
Journal:  Neuroendocrinology       Date:  2004       Impact factor: 4.914

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Characteristics and treatment of mucin-producing tumor of the pancreas.

Authors:  W Kimura; M Makuuchi; A Kuroda
Journal:  Hepatogastroenterology       Date:  1998 Nov-Dec
View more
  7 in total

1.  Genetic polymorphisms of interleukin 1β gene and sporadic pancreatic neuroendocrine tumors susceptibility.

Authors:  Dimitrios Karakaxas; Anna Sioziou; Gerasimos Aravantinos; Ahmet Coker; Ioannis S Papanikolaou; Theodoros Liakakos; Christos Dervenis; Maria Gazouli
Journal:  World J Gastrointest Oncol       Date:  2016-06-15

2.  Association of -308G/A and -238G/A polymorphisms of TNF-α and osteosarcoma risk.

Authors:  Zhongwei Zhao; Xiangyu Tang; Kai Song; Xiang Li; Yonggang Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 3.  Neuroendocrine Neoplasms of the Small Bowel and Pancreas.

Authors:  Ashley Kieran Clift; Mark Kidd; Lisa Bodei; Christos Toumpanakis; Richard P Baum; Kjell Oberg; Irvin M Modlin; Andrea Frilling
Journal:  Neuroendocrinology       Date:  2019-09-27       Impact factor: 5.135

4.  Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study.

Authors:  Qiwen Ben; Jie Zhong; Jian Fei; Haitao Chen; Lifen Yv; Jihong Tan; Yaozong Yuan
Journal:  Sci Rep       Date:  2016-10-26       Impact factor: 4.379

5.  Genetic Variants of the MIF Gene and Susceptibility of Rectal Cancer.

Authors:  Dongyu Chuo; Dapeng Lin; Mingdi Yin; Yuze Chen
Journal:  Pharmgenomics Pers Med       Date:  2021-01-12

6.  A systematic review and network meta-analysis of single nucleotide polymorphisms associated with pancreatic cancer risk.

Authors:  Zhuo-Miao Ye; Li-Juan Li; Ming-Bo Luo; Hong-Yuan Qing; Jing-Hui Zheng; Chi Zhang; Yun-Xin Lu; You-Ming Tang
Journal:  Aging (Albany NY)       Date:  2020-11-20       Impact factor: 5.682

7.  RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors.

Authors:  Yonghe Wu; Lucas Tedesco; Kristin Lucia; Anna M Schlitter; Jose Monteserin Garcia; Irene Esposito; Christoph J Auernhammer; Marily Theodoropoulou; Eduardo Arzt; Ulrich Renner; Günter K Stalla
Journal:  Oncotarget       Date:  2016-09-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.